Covid-19

Home>Tag: Covid-19
Jan 14 2021

Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

By |2021-01-13T18:47:16-05:00January 14th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 14, 2021 – Halberd Corp. (OTC PINK: "HALB") announced the filing of a provisional patent application on a proprietary combination of nutritional supplements (melatonin, zinc and Vitamin D) combined with low dose Naltrexone designed to reduce the severity of Covid-19 symptoms.  This proprietary combination of nutritional supplements is based on numerous ...

Jan 12 2021

Halberd Corporation’s Covid-19 Efforts Recognized in Wall Street PR News Article

By |2021-01-11T19:57:47-05:00January 12th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, January 12, 2021 – Halberd Corp. (OTC PINK: "HALB") was recently included alongside Novavax Inc (NASDAQ:NVAX) and Moderna Inc (NASDAQ:MRNA) in a recent Wall Street PR article on Covid-19 related stocks poised to have an impact in 2021.  Halberd was noted to be working in a different direction from the vaccine producers.  ...

Dec 17 2020

Halberd Corporation Pursues Extracorporeal Radio Frequency Treatment Against Covid-19

By |2020-12-16T20:11:40-05:00December 17th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 17, 2020 – Halberd Corp. (OTC PINK: "HALB") announced they are pursuing development of their latest extracorporeal treatment variation in the fight against COVID-19.  Halberd’s provisional patent application, “Method For Treating And Curing Covid-19 Infection By Utilizing Radio Frequency Extracorporeally To Eradicate The Virus,” was filed last month.  The procedure is ...

Dec 14 2020

Halberd Corp. Research Yields Potent SARS-CoV-2 Antibody

By |2020-12-13T17:40:49-05:00December 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 14, 2020 – Halberd Corporation (OTC PINK: "HALB") announced its proprietary, highly potent, neutralizing antibody against SARS-CoV-2, which demonstrated very strong receptor specificity and inhibition of SARS-CoV-2 replication.  Halberd’s anti-Spike protein monoclonal antibody, recently filed with the United States Patent Office, underwent in vitro studies at Arizona State University (ASU). Based ...

Dec 10 2020

Halberd Corporation Discusses Positive Antibody Test Results Against COVID-19 with The Stock Day Podcast

By |2020-12-09T21:39:40-05:00December 10th, 2020|Featured, Investor News, News|1 Comment

Phoenix, December 10th, 2020 (Newsfile Corp.) -- The Stock Day Podcast welcomed Halberd Corporation (HALB) (“the Company”), a company with a patented extracorporeal treatment applicable to many hard-to-cure blood-borne and neurological diseases, including Covid-19, other viruses, and PTSD. President and CEO of the Company, William A. Hartman, joined Stock Day host Everett Jolly. Jolly began ...

Dec 7 2020

Halberd Corp. Research Yields Promising SARS-CoV-2 Antibody in Laboratory Testing

By |2020-12-06T16:39:08-05:00December 7th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 7, 2020 – Halberd Corporation (OTC PINK: "HALB") announced the promising results of laboratory testing on their new patent pending SARS-COV-2 monoclonal antibody generated through their university research.  The antibody testing to date has shown extremely potent action against the SARS-CoV-2 spike protein.  Scientific details of the testing to date will ...

Dec 2 2020

Halberd Corporation’s Covid-19 Technology Recognized by Momentum Observer

By |2020-12-01T19:46:42-05:00December 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, December 2, 2020 – Halberd Corp. (OTC PINK: "HALB") was recently included in a Momentum Observer article on Covid-19 along with big pharma companies Pfizer (PFE: NYSE), Moderna (MRNA: NASDAQ), BioNTech (BNTX: NASDAQ) and AstraZeneca (AZN: NASDAQ).  The article featured Halberd's nasal spray currently under development that could be an effective alternative ...

Nov 25 2020

Halberd Corp. CEO Interviewed on Money TV;
Discusses 2020 Accomplishments and Plans

By |2020-11-24T20:59:01-05:00November 25th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 25, 2020 – Halberd Corporation (OTC-PINK: "HALB") Chairman, President and CEO, William A. Hartman, was interviewed this week by host, Donald Baillargeon, on Money TV.  Mr. Hartman recapped the company’s accomplishments, describing its most promising technologies and described the unique applications perceived, including a sneak peek at the future. Mr. Hartman ...

Nov 19 2020

Halberd Corporation Files for Patent Protection on Covid-19 Extracorporeal Treatment Variation

By |2020-11-18T19:10:48-05:00November 19th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 19, 2020 – Halberd Corp. (OTC PINK: "HALB") reported the filing of a provisional patent application on a variation of Halberd’s patented extracorporeal method to treat/eradicate Covid-19 from a patient’s blood.  By using an extracorporeal (outside the body) treatment method, the patient is exposed to far fewer potential negative side effects ...

Nov 12 2020

Halberd Corporation Reveals Patent-Pending Fluorescent Antibody’s Wide Role in Covid-19 Detection & Treatment

By |2020-11-11T20:25:36-05:00November 12th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, November 12, 2020 – Halberd Corporation (OTC PINK: "HALB") today disclosed information on their patent-pending fluorescent anti-Spike protein monoclonal antibodies against Covid-19 developed in conjunction with Dr. Qiang (Shawn) Chen of Arizona State University.  The salient feature of Halberd’s new class of antibody is that it fluoresces in the presence of Covid-19 ...

Go to Top